Experimental KRAS G12D Pill Shrank Tumors in 41% of Previously Treated Pancreatic Cancer Patients in Early Trial

Verastem’s KRAS G12D pill shrank tumors in 41% of 22 previously treated pancreatic cancer patients in early, company-reported data. What it means.

Have A Referral?